Megnica Tablet contains Flunarizine 10mg, a selective calcium channel blocker primarily used for the prophylaxis of migraine and management of vestibular disorders. Flunarizine acts by inhibiting the influx of calcium ions into vascular smooth muscle and neuronal cells, thereby exerting a vasodilatory effect and stabilizing neuronal excitability. This mechanism helps reduce the frequency and severity of migraine attacks and alleviates symptoms associated with vertigo and balance disturbances. Megnica is indicated for patients experiencing frequent migraine episodes, including those with aura, and for individuals suffering from peripheral and central vestibular vertigo. The tablet is generally well-tolerated; however, it should be used cautiously in patients with a history of depression, extrapyramidal symptoms, or Parkinson’s disease due to potential adverse effects such as drowsiness, weight gain, and extrapyramidal symptoms. The recommended dosage is typically one 10mg tablet once daily, preferably at bedtime, to minimize daytime sedation. Megnica should be prescribed after a thorough evaluation of the patient’s medical history and concomitant medications to avoid interactions. Regular monitoring is advised during long-term therapy to assess efficacy and detect any adverse reactions promptly.